Taken together, the current and previous studies support the idea that extrahepatic angiogenesis due to VEGF pathway upregulation plays an important role in portal hypertension and manifests VEGF signaling antagonism as a potent therapeutic strategy in portal hypertension. This evidence concerns the gene VEGFA and portal hypertension.